Jason T Yustein

List of Publications by Year
in descending order

52 papers	3,294 citations	236925 25 h-index	197818 49 g-index
54 all docs	54 docs citations	54 times ranked	6275 citing authors

#	Article	IF	Citations
1	The interplay between MYC and HIF in cancer. Nature Reviews Cancer, 2008, 8, 51-56.	28.4	535
2	Myc Stimulates Nuclearly Encoded Mitochondrial Genes and Mitochondrial Biogenesis. Molecular and Cellular Biology, 2005, 25, 6225-6234.	2.3	527
3	Global mapping of c-Myc binding sites and target gene networks in human B cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17834-17839.	7.1	462
4	Proteoglycan 4 Expression Protects Against the Development of Osteoarthritis. Science Translational Medicine, 2013, 5, 176ra34.	12.4	156
5	High ALDH Activity Identifies Chemotherapy-Resistant Ewing's Sarcoma Stem Cells That Retain Sensitivity to EWS-FLI1 Inhibition. PLoS ONE, 2010, 5, e13943.	2.5	130
6	Matrix infrared spectra of NUN formed by the insertion of uranium atoms into molecular nitrogen. Journal of Chemical Physics, 1993, 98, 6070-6074.	3.0	117
7	The Adolescent and Young Adult with Cancer: State of the Art - Bone Tumors. Current Oncology Reports, 2013, 15, 296-307.	4.0	90
8	Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. Journal of Clinical Investigation, 2016, 126, 2678-2688.	8.2	90
9	Poly(ADP-Ribose) Polymerase 1 and Ste20-Like Kinase hKFC Act as Transcriptional Repressors for Gamma-2 Herpesvirus Lytic Replication. Molecular and Cellular Biology, 2003, 23, 8282-8294.	2.3	75
10	Biology and treatment of BurkittÊ¼s lymphoma. Current Opinion in Hematology, 2007, 14, 375-381.	2.5	74
11	Crossâ€spec ies identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Medicine, 2015, 4, 977-988.	2.8	69
12	Tegavivint and the Î²-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. Journal of the National Cancer Institute, 2019, 111, 1216-1227.	6.3	69
13	Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. Journal of Clinical Investigation, 2021, 131, .	8.2	66
14	Cancerâ€™s Achillesâ€™ Heel: Apoptosis and Necroptosis to the Rescue. International Journal of Molecular Sciences, 2017, 18, 23.	4.1	64
15	Fluorinated Eu^{II}-based multimodal contrast agent for temperature- and redox-responsive magnetic resonance imaging. Chemical Science, 2017, 8, 8345-8350.	7.4	60
16	Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Childrenâ€™s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Research, 2019, 8, 493.	1.6	57
17	Recent Insights into Therapy Resistance in Osteosarcoma. Cancers, 2021, 13, 83.	3.7	57
18	Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3534-3539.	7.1	47

#	Article	IF	Citations
19	Pulsed laser evaporation of boron/carbon pellets: Infrared spectra and quantum chemical structures and frequencies for BC2. Journal of Chemical Physics, 1993, 99, 12-17.	3.0	43
20	miRâ€130b directly targets ARHGAP1 to drive activation of a metastatic CDC42â€PAK1â€AP1 positive feedback loop in Ewing sarcoma. International Journal of Cancer, 2017, 141, 2062-2075.	5.1	43
21	Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma. Oncotarget, 2017, 8, 96738-96752.	1.8	41
22	Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential. BMC Cancer, 2016, 16, 869.	2.6	40
23	Comparative studies of a new subfamily of human Ste20-like kinases: homodimerization, subcellular localization, and selective activation of MKK3 and p38. Oncogene, 2003, 22, 6129-6141.	5.9	39
24	Research models and mesenchymal/epithelial plasticity of osteosarcoma. Cell and Bioscience, 2021, 11, 94.	4.8	34
25	MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin. Scientific Reports, 2019, 9, 19089.	3.3	26
26	Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis. British Journal of Cancer, 2015, 113, 1289-1297.	6.4	24
27	Reproducible and Characterized Method for Ponatinib Encapsulation into Biomimetic Lipid Nanoparticles as a Platform for Multi-Tyrosine Kinase-Targeted Therapy. ACS Applied Bio Materials, 2020, 3, 6737-6745.	4.6	21
28	Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties. Oncotarget, 2017, 8, 77292-77308.	1.8	21
29	Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma. Cancer Research, 2021, 81, 199-212.	0.9	20
30	KFC, a Ste20-like kinase with mitogenic potential and capability to activate the SAPK/JNK pathway. Oncogene, 2000, 19, 710-718.	5.9	19
31	Generation of patientâ€derived tumor xenografts from percutaneous tumor biopsies in children with bone sarcomas. Pediatric Blood and Cancer, 2019, 66, e27579.	1.5	18
32	Reactions of pulsed-laser evaporated lithium atoms with O2 and N2O. Chemical Physics, 1994, 189, 343-349.	1.9	15
33	Reactions of Pulsed-Laser-Evaporated Thallium Atoms with O2. Matrix Infrared Spectra of New TlO2 Species. Trends in Group 13 Dioxides and Dioxide Anions. Journal of Physical Chemistry A, 1997, 101, 9077-9084.	2.5	15
34	Coamplification of <scp>M</scp>yc/<scp>P</scp>vt1 and homozygous deletion of <scp>N</scp>lrp1 locus are frequent genetics changes in mouse osteosarcoma. Genes Chromosomes and Cancer, 2015, 54, 796-808.	2.8	15
35	Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways. Cancer Letters, 2020, 469, 195-206.	7.2	13
36	Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117857119.	7.1	13

#	Article	IF	Citations
37	Tyrosine Kinase Expression Profiles of Chicken Erythro- Progenitor Cells and Oncogene- Transformed Erythroblasts. Journal of Biomedical Science, 1998, 5, 93-100.	7.0	10
38	Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells. Advances in Cell and Gene Therapy, 2021, 4, e99.	0.9	10
39	p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma. Oncogene, 2021, 40, 1176-1190.	5.9	10
40	K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	10
41	Dual-Mode Tumor Imaging Using Probes That Are Responsive to Hypoxia-Induced Pathological Conditions. Biosensors, 2022, 12, 478.	4.7	10
42	Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo. Annals of Surgical Oncology, 2019, 26, 4782-4790.	1.5	8
43	Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma. Cancers, 2021, 13, 2696.	3.7	6
44	Upregulation of miR181a/miR212 Improves Myogenic Commitment in Murine Fusion-Negative Rhabdomyosarcoma. Frontiers in Physiology, 2021, 12, 701354.	2.8	6
45	InÂVitro and InÂVivo Characterization of a Preclinical Irradiation-Adapted Model for Ewing Sarcoma. International Journal of Radiation Oncology Biology Physics, 2018, 101, 118-127.	0.8	5
46	Abdominal undifferentiated small round cell tumor with unique translocation (X;19)(q13;q13.3). Pediatric Blood and Cancer, 2010, 54, 1041-1044.	1.5	4
47	Transglutaminase-2 promotes metastatic and stem-like phenotypes in osteosarcoma. American Journal of Cancer Research, 2018, 8, 1752-1763.	1.4	4
48	Nanodelivery Systems Face Challenges and Limitations in Bone Diseases Management. Advanced Therapeutics, 2021, 4, 2100152.	3.2	3
49	Detection of Plasma MicroRNA Signature in Osteosarcoma Patients. Methods in Molecular Biology, 2018, 1699, 113-118.	0.9	1
50	Long non-coding RNAs regulation of therapeutic resistance. , 2019, 2, 550-567.		1
51	Abstract 405: The role of GALNT14 in chemoresistant and metastatic osteosarcoma. , 2021, , .		0
52	Abstract 704: Development of a patient-derived xenograft (PDX) modeling program to enable pediatric precision medicine. Cancer Research, 2022, 82, 704-704.	0.9	0